Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.08.2025 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | set forth by specific reference in such a filing. Item 4.02 Non-Reliance on Previously Issued Financial Statements or a |
| 14.08.2024 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | forth by specific reference in such a filing. Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Rela |
| 10.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 02.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 21.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 13.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 22.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 01.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rrants is incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
Stammdaten
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Unternehmen & Branche
| Name | Eledon Pharmaceuticals, Inc. |
|---|---|
| Ticker | ELDN |
| CIK | 0001404281 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 211,9 Mio. USD |
| Beta | 0,84 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -45,617,000 | -0.52 | 169,009,000 | 81,085,000 | |
| 2025-09-30 | 10-Q | -17,459,000 | -0.21 | 129,857,000 | 35,360,000 | |
| 2025-06-30 | 10-Q | -11,216,000 | -0.13 | 144,909,000 | 50,334,000 | |
| 2025-03-31 | 10-Q | -6,495,000 | -0.08 | 161,308,000 | 58,886,000 | |
| 2024-12-31 | 10-K | -36,184,000 | -0.66 | 177,405,000 | 62,446,000 | |
| 2024-09-30 | 10-Q | 76,971,000 | -0.28 | 114,576,000 | 20,364,000 | |
| 2024-06-30 | 10-Q | -44,907,000 | -0.92 | 120,483,000 | -64,195,000 | |
| 2024-03-31 | 10-Q | -23,631,000 | -0.79 | 80,818,000 | -70,422,000 | |
| 2023-12-31 | 10-K | -116,537,000 | -4.73 | 89,066,000 | -48,486,000 | |
| 2023-09-30 | 10-Q | -9,906,000 | -0.33 | 96,069,000 | 35,597,000 | |
| 2023-06-30 | 10-Q | -65,760,000 | -2.74 | 106,785,000 | 43,768,000 | |
| 2023-03-31 | 10-Q | -10,772,000 | -0.75 | 82,306,000 | 74,792,000 | |
| 2022-12-31 | 10-K | -87,966,000 | -6.16 | 92,793,000 | 84,183,000 | |
| 2022-09-30 | 10-Q | -10,471,000 | -0.73 | 149,586,000 | 141,093,000 | |
| 2022-06-30 | 10-Q | -9,247,000 | -0.65 | 154,706,000 | 149,379,000 | |
| 2022-03-31 | 10-Q | -9,864,000 | -0.69 | 161,378,000 | 156,318,000 | |
| 2021-12-31 | 10-K | -34,506,000 | -2.33 | 170,548,000 | 163,995,000 | |
| 2021-09-30 | 10-Q | -9,817,000 | -0.66 | 177,170,000 | 170,748,000 | |
| 2021-06-30 | 10-Q | -7,384,000 | -0.50 | 184,305,000 | 178,521,000 | |
| 2021-03-31 | 10-Q | -8,499,000 | 191,682,000 | 183,871,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.